|
" HDL and LDL: "
Cedó, LídiaReddy, Srinivasa TMato, EugèniaBlanco-Vaca, FranciscoEscolà-Gil, Joan Carles
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
901408
|
| Doc. No
|
:
|
LA9f47c132
|
| Title & Author
|
:
|
HDL and LDL: [Article]. Potential New Players in Breast Cancer Development.\ Cedó, LídiaReddy, Srinivasa TMato, EugèniaBlanco-Vaca, FranciscoEscolà-Gil, Joan Carles
|
| Date
|
:
|
2019
|
| Title of Periodical
|
:
|
UCLA
|
| Abstract
|
:
|
Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality in women. The identification of risk factors can improve prevention of cancer, and obesity and hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work, we review the progress to date in research on the potential role of the main cholesterol transporters, low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although some studies have failed to find associations between lipoproteins and breast cancer, some large clinical studies have demonstrated a direct association between LDL cholesterol levels and breast cancer risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast cancer cells and experimental mouse models of breast cancer have demonstrated an important role for cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate different inflammation-related pathways, thereby enhancing cell proliferation and migration and inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
|
| |